Intercept Pharmaceuticals Inc (ICPT) Given Average Recommendation of “Hold” by Brokerages

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has been assigned an average rating of “Hold” from the twenty-four research firms that are covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $107.07.

A number of brokerages have commented on ICPT. Wedbush reissued a “buy” rating on shares of Intercept Pharmaceuticals in a report on Friday, May 18th. Zacks Investment Research raised Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, February 19th. Oppenheimer reissued a “hold” rating on shares of Intercept Pharmaceuticals in a report on Tuesday, May 8th. BidaskClub lowered Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 24th. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $58.00 price objective on shares of Intercept Pharmaceuticals in a report on Tuesday, May 8th.

In other news, major shareholder Francesco Micheli acquired 390,625 shares of the company’s stock in a transaction that occurred on Monday, April 9th. The shares were acquired at an average price of $64.00 per share, for a total transaction of $25,000,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Mark Pruzanski acquired 7,812 shares of the company’s stock in a transaction that occurred on Monday, April 9th. The stock was purchased at an average price of $64.00 per share, for a total transaction of $499,968.00. Following the purchase, the chief executive officer now owns 11,642 shares of the company’s stock, valued at approximately $745,088. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 399,608 shares of company stock valued at $25,574,912. 4.90% of the stock is currently owned by corporate insiders.



A number of institutional investors have recently bought and sold shares of ICPT. US Bancorp DE lifted its stake in Intercept Pharmaceuticals by 821.6% in the first quarter. US Bancorp DE now owns 1,751 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 1,561 shares during the last quarter. DSC Advisors L.P. purchased a new position in Intercept Pharmaceuticals in the fourth quarter valued at approximately $204,000. Amalgamated Bank purchased a new position in Intercept Pharmaceuticals in the fourth quarter valued at approximately $209,000. Virtu Financial LLC purchased a new position in Intercept Pharmaceuticals in the fourth quarter valued at approximately $234,000. Finally, Opus Point Partners Management LLC lifted its stake in Intercept Pharmaceuticals by 19.0% in the first quarter. Opus Point Partners Management LLC now owns 4,496 shares of the biopharmaceutical company’s stock valued at $277,000 after purchasing an additional 717 shares during the last quarter. Institutional investors and hedge funds own 66.27% of the company’s stock.

Intercept Pharmaceuticals traded up $2.58, reaching $84.82, during midday trading on Thursday, MarketBeat Ratings reports. The stock had a trading volume of 560,193 shares, compared to its average volume of 796,441. Intercept Pharmaceuticals has a 12 month low of $51.05 and a 12 month high of $135.59. The firm has a market capitalization of $2.45 billion, a price-to-earnings ratio of -5.90 and a beta of -1.78. The company has a debt-to-equity ratio of -6.88, a current ratio of 4.58 and a quick ratio of 4.58.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($3.22) EPS for the quarter, beating analysts’ consensus estimates of ($3.41) by $0.19. Intercept Pharmaceuticals had a negative return on equity of 573.64% and a negative net margin of 241.33%. The business had revenue of $35.96 million during the quarter, compared to analyst estimates of $38.44 million. During the same period in the previous year, the company posted ($3.61) EPS. The firm’s revenue was up 70.9% compared to the same quarter last year. sell-side analysts expect that Intercept Pharmaceuticals will post -11.43 EPS for the current year.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply